Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 199 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Uveitis Clear all
Not yet recruiting Phase 1 Interventional

A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis

NCT07427628
View directory record Official record
Conditions
Non Infectious Uveitis
Interventions
TRX103
Biological
Lead sponsor
Quan Dong Nguyen
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 21, 2026, 12:04 PM EDT
Completed Phase 2 Interventional

Leflunomide to Treat Uveitis

NCT00001863
View directory record Official record
Conditions
Uveitis
Interventions
Leflunomide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 12:04 PM EDT
Not listed Phase 1 Interventional

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636
View directory record Official record
Conditions
Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Celecoxib
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 21, 2026, 12:04 PM EDT
Not listed Phase 1 Interventional

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120311
View directory record Official record
Conditions
Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Dexamethasone
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 21, 2026, 12:04 PM EDT
Completed No phase listed Observational

Screening for NEI Clinical Studies

NCT00001734
View directory record Official record
Conditions
Conjunctivitis, Iritis, Keratitis, Retinitis, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 12:04 PM EDT
Not listed No phase listed Observational

Uveitis in Relation to Perceived Stress: A Prospective Study

NCT01025986
View directory record Official record
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Jul 21, 2026, 12:04 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

NCT01717170
View directory record Official record
Conditions
Intermediate Uveitis, Posterior Uveitis, Pan-uveitis
Interventions
Tocilizumab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jul 21, 2026, 12:04 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography

NCT01746537
View directory record Official record
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 21, 2026, 12:04 PM EDT
Completed Phase 2 Interventional Results available

Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

NCT00130637
View directory record Official record
Conditions
Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Jul 21, 2026, 12:04 PM EDT
Not listed No phase listed Observational

Optical Coherence Tomography (OCT) in Uveitis

NCT02026128
View directory record Official record
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Jul 21, 2026, 12:04 PM EDT
Withdrawn Phase 3 Interventional

Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

NCT01103024
View directory record Official record
Conditions
Uveitis
Interventions
AIN457, Placebo
Biological
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Jul 21, 2026, 12:04 PM EDT
Completed Phase 3 Interventional Results available

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

NCT03841357
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Abatacept Injection, Usual Care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
2 Years to 16 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 21, 2026, 12:04 PM EDT
Terminated Phase 2 Interventional

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

NCT05384249
View directory record Official record
Conditions
Uveitis
Interventions
Izokibep, Placebo
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
36
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 21, 2026, 12:04 PM EDT
Not listed No phase listed Observational

Quality of Life and Visual Function in Uveitis Patients

NCT00407316
View directory record Official record
Conditions
Anterior Uveitis, Posterior Uveitis, Panuveitis, Uveitis
Interventions
Not listed
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2006 · Synced Jul 21, 2026, 12:04 PM EDT
Completed No phase listed Observational

VCRC Patient Contact Registry Patient-Reported Data Validation Study

NCT02190942
View directory record Official record
Conditions
Behcet's Disease, Churg-Strauss Syndrome, Giant Cell Arteritis, Wegener Granulomatosis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Jul 21, 2026, 12:04 PM EDT
Completed No phase listed Observational

Uveitis/Intraocular Inflammatory Disease Biobank (iBank)

NCT02656381
View directory record Official record
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
8 Years to 100 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 12:04 PM EDT
Completed No phase listed Observational

Immune Indicators of Uveitis

NCT00089739
View directory record Official record
Conditions
GITR, GITR Ligand, Uveitis, Immunosuppression, Suppressor of Cytokine Secretion
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 12:04 PM EDT
Not listed Phase 4 Interventional

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

NCT03066869
View directory record Official record
Conditions
Uveitis, Posterior, Vasculitis Retinal
Interventions
H.P. ACTHAR GEL
Drug
Lead sponsor
Ocular Immunology and Uveitis Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Jul 21, 2026, 12:04 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

NCT03586284
View directory record Official record
Conditions
Cytomegalovirus Anterior Uveitis
Interventions
Valganciclovir Hydrochloride, Ganciclovir Sodium, Placebo Oral Tablet, Topical placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 21, 2026, 12:04 PM EDT
Completed No phase listed Observational

Differences in Genes and Proteins in Active and Controlled Uveitis

NCT00357266
View directory record Official record
Conditions
Ocular Inflammatory Disease, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 12:04 PM EDT
Completed No phase listed Observational

Study of Eye Tissue for Sarcoidosis

NCT00001278
View directory record Official record
Conditions
Sarcoidosis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 12:04 PM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 21, 2026, 12:04 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 12:04 PM EDT
Completed Phase 2 Interventional

TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis

NCT00001862
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis, Uveitis
Interventions
Enbrel
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 12:04 PM EDT